Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc > Crazy valuations in the stem cell space-$8 billlion company

<< Previous

Bullboard Posts

Next >>

Comment by auricgoldon Dec 28, 2020 3:45pm

131 Views

Post# 32188415

RE:Crazy valuations in the stem cell space-$8 billlion company

Pimpovish, this is exactly why we need to get trading in the US markets. I am sure this will be extremely big once the US invesators hop on board in 2021.

Pimpovish wrote:

When you consider some of the valuations in the stem cell space, buying Hemostemix stock appears to be almost a no brainer. It is abundantly clear based on peer valuations the stock is severely undervalued. While the below noted company uses a different system and method, they are only in Phase 1 and have clinical results based on a single patient. Hemostemix is more evolved and has a market capitalization of $23 million Cdn vs a current valuation of $8.7 billion USD for Fate Therapeutics. This disconnect creates an insane ROI scenario. I actually cannot find a better opportunity. I imagine I won’t be the only one who recognizes this calculated chance at potential wealth creation. Every smallcap stock has inherent risk but each investor must make their own determination based on a strengths and weaknesses analysis. I would love to hear from other investors about possible negatives outside of the 20:1 consolidation which I actually view as a positive.

Fate Therapeutics (NASDAQ:FATE) is a clinical-stage biotechnology company specializing in engineered cell therapies for cancer. Its stock price has shot up from about $20 per share near the beginning of 2020 to over $95 per share following the release of trial data at ASH (American Society of Hematology annual meeting). That gave it a market capitalization of near $8 billion, which is quite remarkable since it is based largely on Phase 1, early clinical-stage data. In this article, I will look at the recently revealed data sets, Fate's platform, and the rest of its pipeline. Then, I will examine whether, at current prices, it might still be undervalued for long-term investors.

Fate Therapeutics jumped 9% after ASH and more than quadrupled in 2020. Natural Killer cell therapy FT516 and CAR NK therapy FT596 had positive results.Dec 18, 2020

seekingalpha.com › article › 43...

Fate Therapeutics Jumped On Supportive Trial Data (NASDAQ ...